Predictors of Outcomes in Patients with Mitral Regurgitation Undergoing Percutaneous Valve Repair

Overview

Journal Sci Rep

Specialty Science

Date 2020 Oct 14

PMID 33051585

Citations 7

Authors

Alberto Polimeni

Michele Albanese

Nadia Salerno

Iolanda Aquila

Jolanda Sabatino

Sabato Sorrentino

Isabella Leo

Michele Cacia

Vincenzo Signorile

Annalisa Mongiardo

Carmen Spaccarotella

Salvatore De Rosa

Ciro Indolfi

Affiliations

Soon will be listed here.

Abstract

Percutaneous mitral valve repair has been increasingly performed worldwide after approval. We sought to investigate predictors of clinical outcome in patients with mitral regurgitation undergoing percutaneous valve repair. The MITRA-UMG study, a single-centre registry, retrospectively collected consecutive patients with symptomatic moderate-to-severe or severe MR undergoing MitraClip therapy. The primary endpoint was the composite of cardiovascular death or rehospitalization for heart failure. Between March 2012 and July 2018, a total of 150 consecutive patients admitted to our institution were included. Procedural success was obtained in 95.3% of patients. The composite primary endpoint of cardiovascular death or rehospitalization for HF was met in 55 patients (37.9%) with cumulative incidences of 7.6%, 26.2%, at 30 days and 1-year, respectively. In the Cox multivariate model, NYHA functional class and left ventricular end-diastolic volume index (LVEDVi), independently increased the risk of the primary endpoint at long-term follow-up. At Kaplan-Meier analysis, a LVEDVi > 92 ml/m was associated with an increased incidence of the primary endpoint. In this study, patients presenting with dilated ventricles (LVEDVi > 92 ml/m) and advanced heart failure symptoms (NYHA IV) at baseline carried the worst prognosis after percutaneous mitral valve repair.

Citing Articles

Intracardiac fluid dynamic analysis: available techniques and novel clinical applications.

Leo I, Cersosimo A, Ielapi J, Sabatino J, Sicilia F, Strangio A BMC Cardiovasc Disord. 2024; 24(1):716.

PMID: 39702022 PMC: 11660877. DOI: 10.1186/s12872-024-04371-3.

Timing of Complete Revascularization in Patients with STEMI and Multivessel Disease: A Systematic Review and Meta-Analysis.

Panuccio G, Salerno N, De Rosa S, Torella D Rev Cardiovasc Med. 2024; 24(2):58.

PMID: 39077406 PMC: 11273107. DOI: 10.31083/j.rcm2402058.

Impact of Percutaneous Mitral Valve Repair on Left Atrial Strain and Atrial Fibrillation Progression.

Romano L, Scalzi G, Malizia B, Aquila I, Polimeni A, Indolfi C J Cardiovasc Dev Dis. 2023; 10(8).

PMID: 37623333 PMC: 10456079. DOI: 10.3390/jcdd10080320.

Cellular and Molecular Mechanisms Underlying Tricuspid Valve Development and Disease.

Salerno N, Panuccio G, Sabatino J, Leo I, Torella M, Sorrentino S J Clin Med. 2023; 12(10).

PMID: 37240563 PMC: 10218952. DOI: 10.3390/jcm12103454.

Epidemiological Trends in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair over the Last Decade: Functional vs. Structural Mitral Regurgitation.

Schneider L, Nita N, Dahme T, Markovic S, Kessler M, Rottbauer W J Clin Med. 2022; 11(5).

PMID: 35268513 PMC: 8911032. DOI: 10.3390/jcm11051422.

References

Zimarino M, Ricci F, Capodanno D, De Innocentiis C, Verrengia E, Swaans M . Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. Cardiovasc Revasc Med. 2019; 21(7):857-864. DOI: 10.1016/j.carrev.2019.11.003. View

Stone G, Lindenfeld J, Abraham W, Kar S, Lim D, Mishell J . Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018; 379(24):2307-2318. DOI: 10.1056/NEJMoa1806640. View

Polimeni A, Anadol R, Munzel T, De Rosa S, Indolfi C, Gori T . Predictors of bioresorbable scaffold failure in STEMI patients at 3 years follow-up. Int J Cardiol. 2018; 268:68-74. DOI: 10.1016/j.ijcard.2018.04.081. View

Ueno T, Sakata R, Iguro Y, Yamamoto H, Ueno M, Ueno T . Impact of subvalvular procedure for ischemic mitral regurgitation on leaflet configuration, mobility, and recurrence. Circ J. 2008; 72(11):1737-43. DOI: 10.1253/circj.cj-08-0449. View

Capodanno D, Adamo M, Barbanti M, Giannini C, Laudisa M, Cannata S . Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. Am Heart J. 2015; 170(1):187-95. DOI: 10.1016/j.ahj.2015.04.010. View

Izumo M, Kuwata S, Ishibashi Y, Suzuki T, Ohara H, Watanabe M . Prognostic impact of transcatheter mitral valve repair in patients with exercise-induced secondary mitral regurgitation. Eur Heart J Cardiovasc Imaging. 2020; 22(5):530-538. DOI: 10.1093/ehjci/jeaa200. View

Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R . Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009; 54(8):686-94. DOI: 10.1016/j.jacc.2009.03.077. View

Stone G, Adams D, Abraham W, Kappetein A, Genereux P, Vranckx P . Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. J Am Coll Cardiol. 2015; 66(3):308-321. DOI: 10.1016/j.jacc.2015.05.049. View

Nishimura R, Otto C, Bonow R, Carabello B, Erwin 3rd J, Fleisher L . 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; 70(2):252-289. DOI: 10.1016/j.jacc.2017.03.011. View

10.

Vakil K, Roukoz H, Sarraf M, Krishnan B, Reisman M, Levy W . Safety and efficacy of the MitraClip® system for severe mitral regurgitation: a systematic review. Catheter Cardiovasc Interv. 2013; 84(1):129-36. DOI: 10.1002/ccd.25347. View

11.

Nickenig G, Estevez-Loureiro R, Franzen O, Tamburino C, Vanderheyden M, Luscher T . Percutaneous mitral valve edge-to-edge repair: in-hospital results and 1-year follow-up of 628 patients of the 2011-2012 Pilot European Sentinel Registry. J Am Coll Cardiol. 2014; 64(9):875-84. DOI: 10.1016/j.jacc.2014.06.1166. View

12.

Bedogni F, Testa L, Popolo Rubbio A, Bianchi G, Grasso C, Scandura S . Real-World Safety and Efficacy of Transcatheter Mitral Valve Repair With MitraClip: Thirty-Day Results From the Italian Society of Interventional Cardiology (GIse) Registry Of Transcatheter Treatment of Mitral Valve RegurgitaTiOn (GIOTTO). Cardiovasc Revasc Med. 2020; 21(9):1057-1062. DOI: 10.1016/j.carrev.2020.01.002. View

13.

Obadia J, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N . Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018; 379(24):2297-2306. DOI: 10.1056/NEJMoa1805374. View

14.

Zoghbi W, Enriquez-Sarano M, Foster E, Grayburn P, Kraft C, Levine R . Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003; 16(7):777-802. DOI: 10.1016/S0894-7317(03)00335-3. View

15.

Debonnaire P, Van De Heyning C, El Haddad M, Coussement P, Paelinck B, de Ceuninck M . Left Ventricular End-Systolic Dimension and Outcome in Patients With Heart Failure Undergoing Percutaneous MitraClip Valve Repair for Secondary Mitral Regurgitation. Am J Cardiol. 2020; 126:56-65. DOI: 10.1016/j.amjcard.2020.03.045. View

16.

Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm P . [2017 ESC/EACTS Guidelines for the management of valvular heart disease]. Kardiol Pol. 2018; 76(1):1-62. DOI: 10.5603/KP.2018.0013. View

17.

Buzzatti N, Denti P, Scarfo I, Giambuzzi I, Schiavi D, Ruggeri S . Mid-term outcomes (up to 5 years) of percutaneous edge-to-edge mitral repair in the real-world according to regurgitation mechanism: A single-center experience. Catheter Cardiovasc Interv. 2018; 94(3):427-435. DOI: 10.1002/ccd.28029. View

18.

Puls M, Lubos E, Boekstegers P, von Bardeleben R, Ouarrak T, Butter C . One-year outcomes and predictors of mortality after MitraClip therapy in contemporary clinical practice: results from the German transcatheter mitral valve interventions registry. Eur Heart J. 2015; 37(8):703-12. PMC: 4761401. DOI: 10.1093/eurheartj/ehv627. View

19.

Taramasso M, Maisano F, Latib A, Denti P, Buzzatti N, Cioni M . Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention. 2014; 10(6):746-52. DOI: 10.4244/EIJV10I6A128. View

20.

Mirabel M, Iung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde J . What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. Eur Heart J. 2007; 28(11):1358-65. DOI: 10.1093/eurheartj/ehm001. View